EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clinical significance and impact of gastric non‐ Helicobacter pylori Helicobacter species in gastric disease

Emily Taillieu iD, Chloë De Witte iD, Heiko De Schepper iD, Wouter Van Moerkercke, Sophie Rutten, Stijn Michiels, Yuna Arnst, Sofie De Bruyckere, Sven Francque iD, Frauke van Aert, Christophe George, Emma Callewaert und 8 weitere

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2023. Verfasst von Emily Taillieu und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium. Hauptthemen laut MEDLINE: Helicobacter pylori, Helicobacter Infections, Stomach Neoplasms, Lymphoma, B-Cell, Marginal Zone. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Gastric non‐ Helicobacter pylori Helicobacter (NHPH) species naturally associated with animals have been linked with gastric disease in human patients.

Aim

The prevalence and clinical significance of zoonotic gastric NHPHs was determined in large and well‐defined, H. pylori ‐negative, gastric patient populations.

Methods

Patients were retrospectively ( n = 464) and prospectively ( n = 65) included for gastric biopsy collection: chronic gastritis (CG), peptic ulcer disease and gastric MALT lymphoma, without identified aetiology. PCR and sequencing was performed for the detection of gastric Helicobacter species. Retrospectively, asymptomatic gastric bypass patients ( n = 38) were included as controls. Prospectively, additional saliva samples and symptom and risk factor questionnaires were collected. In this group, patients with gastric NHPH infection were administered standard H. pylori eradication therapy and underwent follow‐up gastroscopy post‐therapy.

Results

In the retrospective samples, the prevalence of gastric NHPHs was 29.1%, while no gastric NHPHs were detected in control biopsies. In the prospective cohort, a similar proportion tested positive: 27.7% in gastric tissue and 20.6% in saliva. The sensitivity and accuracy for the detection of gastric NHPHs in saliva compared to gastric tissue was 27.8% and 69.8% respectively. Following eradication therapy, clinical remission was registered in 12 of 17 patients, histological remission in seven of nine and eradication in four of eight patients.

Conclusion

These findings suggest a pathophysiological involvement of NHPHs in gastric disease. Patients presenting with gastric complaints may benefit from routine PCR testing for zoonotic gastric NHPHs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Helicobacter pyloriHelicobacter InfectionsStomach NeoplasmsLymphoma, B-Cell, Marginal ZoneAnimalsHumansRetrospective StudiesClinical RelevanceProspective StudiesAnti-Bacterial Agents

Stichwörter der Autor:innen

animalgastric Helicobacter speciesgastric diseasehumannon-Helicobacter pylori Helicobacter specieszoonosis

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pathobiology, Pharmacology and Zoological Medicine, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
  • Department of Gastroenterology and Hepatology, University Hospital Antwerp, Antwerp University, Edegem, Belgium.
  • Department of Gastroenterology and Hepatology, General Hospital Groeninge, Kortrijk, Belgium.
  • Department of Pathological Anatomy, General Hospital Groeninge, Kortrijk, Belgium.
  • Department of Gastroenterology and Hepatology, General Hospital Maria Middelares, Ghent, Belgium.

ORCID-Profile: Emily Taillieu, Chloë De Witte, Heiko De Schepper, Sven Francque, Koen Chiers, Freddy Haesebrouck, Christophe Van Steenkiste

Zitieren

APA

Taillieu, E., De Witte, C., De Schepper, H., Van Moerkercke, W., Rutten, S., Michiels, S., Arnst, Y., De Bruyckere, S., Francque, S., van Aert, F., George, C., Callewaert, E., Callewaert, T., Vanneste, G., Vanderstraeten, E., Van Heddegem, N., Vansteelant, M., Chiers, K., Haesebrouck, F., & Van Steenkiste, C. (2023). Clinical significance and impact of gastric non‐ Helicobacter pylori Helicobacter species in gastric disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17488

Vancouver

Taillieu E, De Witte C, De Schepper H, Van Moerkercke W, Rutten S, Michiels S, et al. Clinical significance and impact of gastric non‐ Helicobacter pylori Helicobacter species in gastric disease. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17488

BibTeX
@article{Taillieu2023,
  author = {Taillieu, Emily and De Witte, Chloë and De Schepper, Heiko and Van Moerkercke, Wouter and Rutten, Sophie and Michiels, Stijn and Arnst, Yuna and De Bruyckere, Sofie and Francque, Sven and van Aert, Frauke and George, Christophe and Callewaert, Emma and Callewaert, Tiene and Vanneste, Glenn and Vanderstraeten, Erik and Van Heddegem, Nina and Vansteelant, Margaux and Chiers, Koen and Haesebrouck, Freddy and Van Steenkiste, Christophe},
  title = {Clinical significance and impact of gastric non‐ Helicobacter pylori Helicobacter species in gastric disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17488}
}
Kostenlos starten →